SCHEMBL1834809

SCHEMBL1834809

CCC1(C(=O)O)CCC(C)CC1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 1/20 0.34
ALDH1A1 P00352 4/20 0.33
FFAR3 O14843 1/20 0.32
KDM4E B2RXH2 4/20 0.32
ALOX15 P16050 1/20 0.32
POLB P06746 1/20 0.32
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
NFKB1 P19838 1/20 0.30
MAPK1 P28482 1/20 0.30
THPO P40225 1/20 0.30
STAT6 P42226 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13464557 0.92 CYP1A2 (0.43) CYP1A2CYP2C19CYP2C9ALDH1A1
SCHEMBL13464532 0.88 CYP1A2 (0.42) CYP1A2CYP2C19ALDH1A1FFAR3
SCHEMBL605108 0.83 CYP2C19 (0.34) CYP2C19ALDH1A1FFAR3NPC1LMNA
SCHEMBL19839393 0.83 KDM4E (0.38) CYP1A2CYP2C19CYP2C9ALDH1A1FFAR3
SCHEMBL245571 0.81
SCHEMBL30716833 0.81 CYP2C19 (0.42) CYP2C19ALDH1A1FFAR3
SCHEMBL16875354 0.81 CYP2C19 (0.42) CYP1A2CYP2C19ALDH1A1KDM4EALOX15
SCHEMBL10501307 0.81 ALDH1A1 (0.35) CYP2C19ALDH1A1FFAR3KDM4EPOLB
SCHEMBL16875355 0.81 CYP2C19 (0.42) CYP1A2CYP2C19ALDH1A1KDM4EALOX15
SCHEMBL22341255 0.81 ALDH1A1 (0.38) CYP1A2CYP2C19CYP2C9ALDH1A1FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563742-B2 Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use HIGH POINT PHARMACEUTICALS, LLC (US) 2013-10-22 US disclosed
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-10-18 US disclosed
EP-2320738-A1 SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TransTech Pharma, Inc. (US) 2011-05-18 EP disclosed
US-20100056587-A1 Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use VTVX HOLDINGS I LLC 2010-03-04 US disclosed
WO-2010025142-A1 SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 CYP1A2 1277/4885CYP2C19 2273/4885CYP2C9 2375/4885
US-20100056587-A1 Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use MC4R, MC3R, MC5R CYP1A2 2655/4885CYP2C19 1351/4885CYP2C9 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.